FMP
NASDAQ
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
1.48 USD
0.059 (3.99%)
Valuation Date:
Apr 19, 2024 4:00 PM
Share Price on Valuation Date
$1.48
Stock Beta
0.328
Shares Outstanding
987475